Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases.

Ikeda Y, Takano M, Oda K, Kouta H, Goto T, Kudoh K, Sasaki N, Kita T, Kikuchi Y.

Int J Gynecol Cancer. 2013 Feb;23(2):355-60. doi: 10.1097/IGC.0b013e31827de69e.

PMID:
23358182
2.
3.

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.

Li J, Merl M, Lee MX, Kaley K, Saif MW.

Expert Opin Drug Saf. 2010 Mar;9(2):207-13. doi: 10.1517/14740330903555181.

PMID:
20095915
4.

Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.

Harnett P, Buck M, Beale P, Goldrick A, Allan S, Fitzharris B, De Souza P, Links M, Kalimi G, Davies T, Stuart-Harris R.

Int J Gynecol Cancer. 2007 Mar-Apr;17(2):359-66.

PMID:
17362313
5.

Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.

Taïeb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V.

Cancer. 2003 Dec 15;98(12):2664-70.

6.

A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.

Sehgal R, Lembersky BC, Rajasenan KK, Crandall TL, Balaban EP, Pinkerton RA, Kane P, Schmotzer A, Zeh H, Potter DM, Ramanathan RK.

Clin Colorectal Cancer. 2011 Jun;10(2):117-20. doi: 10.1016/j.clcc.2011.03.008. Epub 2011 Apr 28.

PMID:
21859564
7.

Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.

Kudoh K, Takano M, Kouta H, Kikuchi R, Kita T, Miyamoto M, Watanabe A, Kato M, Goto T, Kikuchi Y.

Gynecol Oncol. 2011 Aug;122(2):233-7. doi: 10.1016/j.ygyno.2011.04.046. Epub 2011 May 23.

PMID:
21601912
8.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD.

J Clin Oncol. 2005 May 20;23(15):3509-16.

PMID:
15908661
9.

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.

Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, De Chiara A, Pinto A.

Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16. doi: 10.1007/s00280-009-0941-9. Epub 2009 Feb 15.

PMID:
19219604
11.

Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.

Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A, Grijuela B, Fontanelli R, Solima E, Spatti G, Scibilia G, Kusamura S.

Oncology. 2004;67(5-6):376-81.

PMID:
15713993
12.

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.

Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL.

Br J Cancer. 2006 Feb 27;94(4):481-5.

13.

Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.

Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS.

Oncology. 2009;76(5):333-7. doi: 10.1159/000209962. Epub 2009 Mar 23.

PMID:
19307739
14.

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K.

J Clin Oncol. 2006 Apr 20;24(12):1898-903.

PMID:
16622265
15.

Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.

Li Y, Yang Y, Shang YM, Zheng H.

Indian J Cancer. 2014 Mar;51 Suppl 3:e92-4. doi: 10.4103/0019-509X.154079.

16.

Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.

Steer CB, Chrystal K, Cheong KA, Galani E, Marx GM, Strickland AH, Yip D, Lofts F, Gallagher C, Thomas H, Harper PG.

Gynecol Oncol. 2006 Nov;103(2):439-45. Epub 2006 Apr 27.

PMID:
16643993
17.

A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.

Eisenhauer EL, Zanagnolo V, Cohn DE, Salani R, O'Malley DM, Sutton G, Callahan MJ, Cobb B, Fowler JM, Copeland LJ.

Gynecol Oncol. 2014 Aug;134(2):262-6. doi: 10.1016/j.ygyno.2014.05.030. Epub 2014 Jun 5.

PMID:
24910452
18.

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.

Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi S S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J.

Cancer. 2008 Jun 15;112(12):2733-9. doi: 10.1002/cncr.23489.

19.

Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.

Ferrero A, Logrippo V, Spanu PG, Fuso L, Perotto S, Daniele A, Zola P.

Int J Gynecol Cancer. 2009 Dec;19(9):1529-34. doi: 10.1111/IGC.0b013e3181a8407e.

PMID:
19955931
20.

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.

Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ.

Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7. doi: 10.1007/s00280-009-1069-7. Epub 2009 Aug 4.

PMID:
19652971

Supplemental Content

Support Center